Compare BioNano Genomics Inc (BNGO) vs QUALCOMM, Inc. (QCOM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNano Genomics Inc vs QUALCOMM, Inc. — how do they compare? BioNano Genomics Inc trades at $1.15 (market cap $13.20M), while QUALCOMM, Inc. trades at $178.8 (market cap $187.72B). The key difference: QUALCOMM, Inc. is far larger — about 14221.2× BioNano Genomics Inc's market cap, and QUALCOMM, Inc. pays a 2.07% dividend while BioNano Genomics Inc pays none. Which is the better fit depends on your goals.
| BNGO | QCOM | |
|---|---|---|
Market Cap | $13.20M | $187.72B |
Sector | Health | Technology |
52-Week High | $4.92 | $251.10 |
52-Week Low | $1.09 | $124.07 |
Enterprise Value | $15.81M | $193.19B |
Dividend Yield | — | 2.07% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bionano Genomics (BNGO) trades at $1.17, down 2.5% today, but maintains a bullish technical signal with strong moving average support. The company shows improving fundamentals with revenue stabilizing around $29M annually and narrowing losses, though it remains unprofitable with a -109.95% net margin. Recent positive developments include debt retirement and growing adoption of optical genome mapping technology.
BNGO presents a high-risk, high-reward opportunity with analyst consensus leaning bullish (57% buy ratings). The stock trades at attractive valuation multiples (P/S 0.31, P/B 0.36) but faces execution risks in achieving profitability. Key catalysts include continued technology adoption and potential margin improvement, while persistent losses and competitive pressures remain concerns.
Qualcomm (QCOM) trades at $183.98, down 2.74% on the day, amid a bearish technical signal. The company maintains strong profitability with 54.8% gross margins and 22.31% net income margin, though revenue growth has been modest. Recent earnings have consistently beaten expectations, with Q1 2026 EPS of $2.65 surpassing the $2.56 estimate. Analyst consensus remains positive with a $222.53 price target, representing 21% upside potential from current levels.
Qualcomm faces near-term headwinds from smartphone market softness but is successfully diversifying into automotive and AI data centers. The stock offers value at 19.15x P/E with strong cash flow generation, though competition from Nvidia in PC chips presents execution risk. With 42.65% of analysts rating it Buy and solid balance sheet fundamentals, QCOM presents a compelling long-term opportunity despite technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BioNano Genomics Inc
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →About QUALCOMM, Inc.
Qualcomm develops and licenses wireless technology and designs chips for smartphones. The company's key patents revolve around CDMA and OFDMA technologies, which are standards in wireless communications that are the backbone of all 3G and 4G networks. The firm is a leader in 5G network technology as well. Qualcomm's IP is licensed by virtually all wireless device makers. The firm is also the world's largest wireless chip vendor, supplying nearly every premier handset maker with leading-edge processors. Qualcomm also sells RF-front end modules into smartphones and chips into automotive and Internet of Things markets.
Read more on QCOM →
